VEGFA and hepatocellular carcinoma: Dual immune checkpoint inhibitor (ICI) regimens used to treat advanced hepatocellular carcinoma (HCC) include durvalumab plus tremelimumab and nivolumab plus ipilimumab, but optimal sequencing after progression on the former remains unclear, especially when VEGF-targeted options are limited by comorbidities.